This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

And a mention here aswell 200p short term target............

Trading View
Independent Banking
Source: Insinger de Beaufort, Bloomberg

Accelerating development pipeline

Significant commercial potential: MMI is an emerging biotechnology company
focused in cancer and infectious diseases, both areas of significant commercial
potential. MMIs strategy is to develop drugs to Phase II clinical trial stage and then
commercialise via out-licencing agreements with pharmaceutical companies. Thin
pipelines and patent expiries have acted as a catalyst for a large number of deals
with small cap biotechs such as MMI, even for products which are relatively early
stage. For example a deal with Oxxon Therapeutics could potentially be worth up to
44m in up-front and milestone payments in order to access Xenovas early stage
cancer DISC HSV vector technology. It is also interesting to note recent benchmark
deals for pre clinical early stage compounds with promise - Novartis paid c.$157m to
Xenon and J&J is paying up to $295m in a deal excluding royalties to Arena.
MMI has four R&D divisions:
a) Oncosense (wholly owned) - technology based around the precious metal
ruthenium which is potentially up to 15 times more efficacious than the
most potent platinum anticancer drug.
b) Genvax (JV) - developing DNA vaccines for cancer with Southampton
University/Cancer Research UK Leukaemia Research Fund
c) Viratis (JV) - viral infections with Kings College London
d) Endozyme (wholly owned) - drug resistant Infections working with
Cambridge University/Novartis
MMI also provides technical services to UK academic and commercial institutions
which apart from generating revenues, also provides a stream of potential in -
licensing opportunities.
Tight cost control: Given a current cash balance of 2.6m, MMI has enough cash to
last until Q1 06. Whilst it would not be prudent to discount a future fund raising,
additional cash inflows may come from licensing deals. Furthermore MMIs R&D
expenses are contained via collaborat ions outlined above and also contracting out
to CROs (clinical research organisations).
Strong management: MMIs management has been strengthened recently with the
appointment of Dr James Hoeschele (co-discoverer of Carboplatin, a platinum based
anti-cancer treatment) to work on MMI's leading ruthenium compounds which are
expected to reach the market during 2008.
Strong newslow: During the course of 2005 MMI aims to bring 6 new products into
Phase I/II clinical trials including compounds from MMIs ruthenium based
anticancer programme. The JV Genvax is due to report on Phase II trials treating
follicular lymphoma on the 18th March. These results are expected to be positive
and as such could drive the share price higher despite the recent good run. MMI is
also currently negotiating with a number of potential licensee companies for the
ruthenium technology. Conservative target price of 200p (DCF) generates 50% plus
upside to current share price which 1s 111.5p.
Medical Marketing International (MMG.L) Trading Buy
Biotechnology
UK Equity Research
Alexien Eve Isaac +44 (0)20 7190 7197
Paul Bethell, CFA +44 (0)20 7190 7198
researchldn@insinger.com
Previous close price (p):
116.0
Market cap (m):
62.0
Target Price (p):
200.0
Year End:
March
Net cash position:
2.6m




cheers GF.http://www.bendavidson.co.uk/MMI-02-23-05-trading-view.pdf

I'm out of NLR from yesterday gf although I still hold a small parcel of them.I intend to buy more MMG shares with the proceeds as I think they have further to go..cheers.

More or less thinking the same as you Mitzy although I have transfered money from NLR to MMG I have kept two tranches of NLR.

cheers GF.

GF

Are you keeping you eye on GMC. Sorry about the hijack.

MS

Hi Mickey, no got out last week. Building up a big position in this one. Think it will go for Mitzys 400p target and some.

cheers GF.

Well I rekon 200p by the end of the year gf but say 350p within the next 18 months as the products enter and finish phase 2 trials..no point in selling these just yet..!

Would appear that the SP is going to drift down on small sells and thin volume. MM s will use this opportunity to obtain some stock at lower levels ready for a run up to the 18th.. Not seeing the buyers coming in like we where,a few weeks ago so the MM s can slowly lower the price.110p should hold but wouldnt be to suprised to see 100p. However if SP is going to these levels then i would imagine it will be before the 10th as we run up to the 18th

Notice how the MM s are taking it down on no volume.

Appear to be narrowing the spread to try and encourage some buying.We may see another shake down soon.

Well said m.Decided to buy @113p a few moms back as its the usual marked down price and the rally in the afternoon.

From todays Broker Killik notes......................

Medical Marketing, highlighted in our recent Monthly View, traded up yesterday as Insinger de Beaufort, the broker, put a trading buy with a 200p price target out on the stock. It is highlighting the March 18th as the date for revealing results from the Phase II Genvax trial where progress has been seen as encouraging.

cheers GF.

Dont forget gf that IC have these as a potential 10 bagger from 60p....ie a 600p share price target if the Ruthenium drug is licenced to a big pharma and thats before the Genvax news which is due shortly...I'm still buying and remain confident that my gamble will pay off .

Before the Genvax news?, just when then as I want to plow a lot more in. Have you a date????????

cheers GF. Dont want to miss out but its always a gamble with bios.

cheers GF.

No I have put it down wrong gf.....its Genvax news in March and Ruthenium phase 2 in the next couple of months and hopefully a licensing deal for Ruthenium by the years end.. sorry for the confusion.

Here we go, all blue this morning, on the way back up, JB...

Anyone subscribe to Momentum magazine...

Do you mean TMI the tip sheet,,if so i do..JB

Wow look at the buy volume coming in. People loading up before the Genevax news.
Whats the exact date ????????.

cheers GF.

Yes thats the one... any good...?

18th March GF. I sold out of this at 124p last week, and was hoping for a retracement to 100-105 to get back in. Looks like it might not happen now. Never usually do that but I bet its gonna bite me this time!!